{'fraction_non_alphanumeric': 0.04285714285714286, 'fraction_numerical': 0.005714285714285714, 'mean_word_length': 6.01, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Outcome of Children with Standard‐Risk T‐Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies

Children with T‐lineage acute lymphoblastic leukemia ALL (T‐ALL) historically have had inferior outcomes compared with the children with precursor‐B ALL (B‐ALL). After 1995, the Children's Cancer Group (CCG) treated patients with B‐ and T‐ALL according to the National Cancer Institute (NCI) risk criteria, basing risk stratification on age and white blood cell (WBC) count regardless of immunophenotype. The Pediatric Oncology Group (POG) treated all the patients with T‐ALL on separate, generally more intensive protocols than those used to treat the patients with B‐ALL.